KODIAK SCIENCES INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.28 USD | +2.98% |
|
-2.38% | +7.89% |
| Apr. 04 | UBS Adjusts Kodiak Sciences Price Target to $5 From $3, Maintains Neutral Rating | MT |
| Apr. 01 | Barclays Raises Price Target on Kodiak Sciences to $3 From $2, Maintains Underweight Rating | MT |
Presenter SpeechUnknown Analyst (Analysts)Good afternoon, everyone, and thanks for joining us ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
3.28
USD
Average target price
4.25
USD
Spread / Average Target
+29.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.89% | 172M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- KOD Stock
- News Kodiak Sciences Inc.
- Transcript : Kodiak Sciences Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-13-2023 12
